About this trial
Patient Profile
Relapsed/refractory diffuse large B-cell lymphoma
Where’s this trial being run?
St James’s Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | MO40598 |
|---|---|
| Number: | CTRIAL-IE 18-47 |
| Full Title: | A phase II, open-label, multicentre, randomised study evaluating the safety and efficacy of Polatuzumab Vedotin (Pola) in combination with Mabthera plus Gemcitabine plus Oxaliplatin (R-GemOx) versus R-GemOx in patients with relapsed/refractory diffuse large B-cell lymphoma. |
| Principal Investigator: | Elisabeth Vandenberghe |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Roche |
| Recruitment Started: |
Global: Ireland: |
| Global Recruitment Target: | |
|---|---|
| Ireland Recruitment Target: |